dotMD.com
Join Community
📖Formal Study Breakdown Talk in Gut, Labs & Supplements Space 711+ Logs • Free →🧮Lab Calculator ↓
Reading this clinical breakthrough? See how real patients are applying these numbers in real life. Compare real-world patient outcomes, lab numbers, and doctor visit tips—100% free with a private @handle and zero login wall.
Click to Ask a Question or Post Your Experience ▾
Post to Gut, Labs & Supplements Space (15 Seconds • No Account or Email Required)
Or read existing discussions in Gut, Labs & Supplements Space →
Back to Plain-English 8th-Grade Story
Google Scholar NIH PubMed #42968369
Official NIH NLM MEDLINE / PubMed Citation • PMID: 42968369

A First-In-Human, Randomized, Placebo-Controlled Single and Multiple Ascending Dose Study of Izicopan (INF904), A Second-Generation Oral Small Molecule C5a Receptor Inhibitor, in Healthy Participants

Clinical pharmacology in drug development

Verbatim Formal Study Abstract

In conclusion, izicopan was safe across all single and multiple doses evaluated. Sufficient izicopan exposure was achieved rapidly to exert >90% blockade of C5a-C5aR1 signaling.